beta-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F20%3A00074104" target="_blank" >RIV/00159816:_____/20:00074104 - isvavai.cz</a>

Výsledek na webu

<a href="https://n.neurology.org/content/95/24/e3257" target="_blank" >https://n.neurology.org/content/95/24/e3257</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1212/WNL.0000000000010943" target="_blank" >10.1212/WNL.0000000000010943</a>

Jazyk výsledku

angličtina

Název v původním jazyce

beta-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies

Popis výsledku v původním jazyce

Objective In a multicenter cohort of probable dementia with Lewy bodies (DLB), we tested the hypothesis that beta-amyloid and tau biomarker positivity increases with age, which is modified by APOE genotype and sex, and that there are isolated and synergistic associations with the clinical phenotype. Methods We included 417 patients with DLB (age 45-93 years, 31% women). Positivity on beta-amyloid (A+) and tau (T+) biomarkers was determined by CSF beta-amyloid(1-42) and phosphorylated tau in the European cohort and by Pittsburgh compound B and AV-1451 PET in the Mayo Clinic cohort. Patients were stratified into 4 groups: A-T-, A+T-, A-T+, and A+T+. Results A-T- was the largest group (39%), followed by A+T- (32%), A+T+ (15%), and A-T+ (13%). The percentage of A-T- decreased with age, and A+ and T+ increased with age in both women and men. A+ increased more in APOE epsilon 4 carriers with age than in noncarriers. A+ was the main predictor of lower cognitive performance when considered together with T+. T+ was associated with a lower frequency of parkinsonism and probable REM sleep behavior disorder. There were no significant interactions between A+ and T+ in relation to the clinical phenotype. Conclusions Alzheimer disease pathologic changes are common in DLB and are associated with the clinical phenotype. beta-Amyloid is associated with cognitive impairment, and tau pathology is associated with lower frequency of clinical features of DLB. These findings have important implications for diagnosis, prognosis, and disease monitoring, as well as for clinical trials targeting disease-specific proteins in DLB. Classification of evidence This study provides Class II evidence that in patients with probable DLB, beta-amyloid is associated with lower cognitive performance and tau pathology is associated with lower frequency of clinical features of DLB.

Název v anglickém jazyce

beta-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies

Popis výsledku anglicky

Objective In a multicenter cohort of probable dementia with Lewy bodies (DLB), we tested the hypothesis that beta-amyloid and tau biomarker positivity increases with age, which is modified by APOE genotype and sex, and that there are isolated and synergistic associations with the clinical phenotype. Methods We included 417 patients with DLB (age 45-93 years, 31% women). Positivity on beta-amyloid (A+) and tau (T+) biomarkers was determined by CSF beta-amyloid(1-42) and phosphorylated tau in the European cohort and by Pittsburgh compound B and AV-1451 PET in the Mayo Clinic cohort. Patients were stratified into 4 groups: A-T-, A+T-, A-T+, and A+T+. Results A-T- was the largest group (39%), followed by A+T- (32%), A+T+ (15%), and A-T+ (13%). The percentage of A-T- decreased with age, and A+ and T+ increased with age in both women and men. A+ increased more in APOE epsilon 4 carriers with age than in noncarriers. A+ was the main predictor of lower cognitive performance when considered together with T+. T+ was associated with a lower frequency of parkinsonism and probable REM sleep behavior disorder. There were no significant interactions between A+ and T+ in relation to the clinical phenotype. Conclusions Alzheimer disease pathologic changes are common in DLB and are associated with the clinical phenotype. beta-Amyloid is associated with cognitive impairment, and tau pathology is associated with lower frequency of clinical features of DLB. These findings have important implications for diagnosis, prognosis, and disease monitoring, as well as for clinical trials targeting disease-specific proteins in DLB. Classification of evidence This study provides Class II evidence that in patients with probable DLB, beta-amyloid is associated with lower cognitive performance and tau pathology is associated with lower frequency of clinical features of DLB.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30210 - Clinical neurology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Neurology

ISSN

0028-3878

e-ISSN

—

Svazek periodika

95

Číslo periodika v rámci svazku

24

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

"E3257"-"E3268"

Kód UT WoS článku

000607315800022

EID výsledku v databázi Scopus

—